CureVac GmbH

Breitengrad

48.538

Längengrad

9.057

Focus

CureVac GmbH specialises in RNA molecules synthesised by chemical and enzymatic means. CureVac also carries out its own research in the field of tumour therapy.

Company Profile

CureVac GmbH was founded as a spin-off of the University of Tübingen and has very quickly become established as one of the leading manufacturers of nucleic acids for use as active ingredients in pharmaceutical and therapeutic applications. CureVac GmbH’s portfolio primarily includes three products. 1) Modified and non-modified short (oligo-) RNA molecules are synthesised chemically in accordance with customers’ wishes. 2) The firm also offers RNActive™, an ultra-pure and stabilised form of mRNA that enables tissue and cells to be transfixed effectively. 3) In accordance with customers’ wishes, CureVac can create cDNA libraries in copyright-protected RNActive™ vectors.

Address

Paul-Ehrlich-Str. 15
72076 Tübingen
Germany
Tel: +49 (0)7071- 920530
Fax: +49 (0)7071-9205311
E-Mail: info@curevac.com
http://www.curevac.com

Management

Dr. Ingmar Hörr (CEO)
Dr. Thomas Lander (CMO)
Dr. Florian von der Mülbe (COO)
Dr. Wolfgang Klein (CFO)
Dr. Jochen Probst (CSO)

Contact

Dr. Ingmar Hoerr (ih@curevac.de)

Year of foundation

2000

Number of employees

Financing

2003: 1st financing round; 2006: Series B financing - 22 Mio. €, 2007: additional Series B financing 13 Mio. €(total volume 35 Mio. €).

Certificates/GMP-Standards

CureVac has cGMP production facilities compliant with FDA and EMEA standards

BioProfile

New approach to in vivo tissue generation through RNA technology, with skin tissue as an example